Edaravone

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

DMF submissions in 2020: Industry sustains its filing momentum

In case you thought Covid-19 had slowed down the speed at which generic active pharmaceutical ingr

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-

Does the FDA promote European manufacturers over others? The ice-bucket challenge winner!

This week, Phispers brings you a short analysis on how FDA might be promoting European drugmakers ov